Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.62 |
| ▸ | DRD4 | P21917 | 2/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.60 |
| ▸ | DRD3 | P35462 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.58 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL555464 | 0.95 | KMT2A (0.64) | KMT2AL3MBTL1SIGMAR1MEN1KCNA3 | |
| SCHEMBL5789230 | 0.94 | KMT2A (0.59) | KMT2AL3MBTL1SIGMAR1MEN1KCNA3 | |
| SCHEMBL7549641 | 0.93 | KCNA3 (0.59) | KMT2AL3MBTL1SIGMAR1MEN1KCNA3 | |
| SCHEMBL3892168 | 0.93 | KMT2A (0.61) | KMT2AL3MBTL1SIGMAR1MEN1KCNA3 | |
| SCHEMBL2241423 | 0.93 | KMT2A (0.63) | KMT2AL3MBTL1SIGMAR1MEN1KCNA3 | |
| SCHEMBL178929 | 0.93 | KMT2A (0.63) | KMT2AL3MBTL1SIGMAR1MEN1KCNA3 | |
| SCHEMBL2241424 | 0.93 | KMT2A (0.63) | KMT2AL3MBTL1SIGMAR1MEN1KCNA3 | |
| SCHEMBL1412219 | 0.91 | KMT2A (0.58) | KMT2AL3MBTL1SIGMAR1MEN1KCNA3 | |
| SCHEMBL1412221 | 0.91 | KMT2A (0.58) | KMT2AL3MBTL1SIGMAR1MEN1KCNA3 | |
| SCHEMBL18845342 | 0.90 | SIGMAR1 (0.57) | KMT2AL3MBTL1SIGMAR1MEN1KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605373-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-04-21 | — | — | US | disclosed |
| US-20250120965-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-04-17 | — | — | US | disclosed |
| WO-2024132278-A1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW WATER-SOLUBLE AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) INHIBITORS | UNIVERSITÄT REGENSBURG (DE) | 2024-06-27 | — | — | WO | disclosed |
| EP-4389223-A1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW WATER-SOLUBLE AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) INHIBITORS | Universität Regensburg (DE) | 2024-06-26 | — | — | EP | disclosed |
| EP-4389223-A1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW WATER-SOLUBLE AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) INHIBITORS | Universität Regensburg (DE) | 2024-06-26 | — | — | EP | disclosed |
| CN-111484479-B | Azacyclic compounds, pharmaceutical compositions containing the same, and methods of making and using the same | 四川科伦博泰生物医药股份有限公司 | 2023-06-13 | — | — | CN | disclosed |
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2023010078-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| US-20230021224-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230021224-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-01-19 | — | — | US | disclosed |
| US-5498628-A | ANTIPSYCHOTIC, PSYCHOSTIMULATORY, ANTIAUTISTIC, ANTIDEPRESSANT AND HYPOTENSIVE AGENTS, PARKINSON'S DISEASE | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1996-03-12 | — | — | US | disclosed |
| WO-1996005193-A1 | (AZETIDIN-1-YLALKYL)LACTAMS AS TACHYKININ ANTAGONISTS | PFIZER LIMITED (GB) | 1996-02-22 | — | — | WO | disclosed |
| WO-1996004274-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1996-02-15 | — | — | WO | disclosed |
| WO-1995010519-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1995-04-20 | — | — | WO | disclosed |
| WO-1995007904-A1 | IMIDAZOLONE AND OXAZOLONE DERIVATIVES AS DOPAMINE ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1995-03-23 | — | — | WO | disclosed |
| US-5374731-A | Treatment of high blood pressure, congestive heart failure and viral disorders | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-12-20 | — | — | US | disclosed |
| EP-0410278-B1 | Renin inhibiting aminooligohydroxy-derivatives | HOECHST AG (DE) | 1994-01-19 | — | — | EP | disclosed |
| EP-0417698-A2 | Amino acid derivatives having renin-inhibiting activity, process for their preparation, agents containing them, and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-03-20 | — | — | EP | disclosed |
| EP-0410278-A1 | Renin inhibiting aminooligohydroxy-derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-01-30 | — | — | EP | disclosed |
| EP-0008014-A1 | 1-(4-Aminopiperidino)-3.4-dihydroisoquinoline derivatives, processes for their preparation, pharmaceutical compositions containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605373-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | CUL3, CUL1, CUL5 | KMT2A 2563/4885L3MBTL1 2051/4885SIGMAR1 2901/4885 |
| US-20230021224-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | UBQLN1, CUL1, DCUN1D1 | KMT2A 2316/4885L3MBTL1 2569/4885SIGMAR1 3671/4885 |
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | KMT2A 1920/4885L3MBTL1 4078/4885SIGMAR1 343/4885 |
| US-20250120965-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | UBQLN1, CUL1, DCUN1D1 | KMT2A 2316/4885L3MBTL1 2569/4885SIGMAR1 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.